Dapagliflozin: A sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes

Diabetes Therapy

Volumn 1, Issue 2, 2010, Pages 45-56

  Tahrani, Abd A ^a,b   Barnett, Anthony H ^a,b  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

dapagliflozin; diabetes; inhibitor; SGLT2

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; ASP 1941; BI 10773; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIMEPIRIDE; GLIPIZIDE; INSULIN; INSULIN SENSITIZING AGENT; LIRAGLUTIDE; LX 4211; MEGLITINIDE; METFORMIN; PHLORIZIN; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN;

CLINICAL FEATURE; DEHYDRATION; DIURESIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE BALANCE; GENITAL TRACT INFECTION; GLUCOSE ABSORPTION; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; KIDNEY FAILURE; KIDNEY TUBULE ABSORPTION; MAGNESIUM BLOOD LEVEL; MEAN ARTERIAL PRESSURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORTHOSTATIC HYPOTENSION; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN FUNCTION; RENAL DIABETES; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM URINE LEVEL; UREMIA; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; URINE VOLUME; VAGINA CANDIDIASIS;

EID: 79952728903     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-010-0007-3     Document Type: Review

References (51)

1. International Diabetes Federation. IDF Diabetes Atlas. Available at: www. diabetesatlas. org/book/export/html/36. Accessed April 21, 2010.
2. World Health Organization. Global Strategy on Diet, Physical Activity and Health. Available at: www. who. int/dietphysicalactivity/publications/facts/obesity/en/. Accessed April 21, 2010.
3. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care. 2001; 24: 89-94.
4. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004; 88: 787-835.
5. Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009; 373: 2215-2221.
6. Bonner-Weir S. Islet growth and development in the adult. J Mol Endocrinol. 2000; 24: 297-302.
7. Goldstein BJ. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol. 2002; 90: 3G-10G.
8. Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab. 2003; 284: E671-E678.
9. Nichols GA, Arondekar B, Herman WH. Complications of dysglycemia and medical costs associated with nondiabetic hyperglycemia. Am J Manag Care. 2008; 14: 791-798.
10. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008; 26: 77-82.
11. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321: 405-412.
12. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352: 854-865.
13. Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia. 2006; 49: 434-441.
14. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996; 334: 574-579.
15. Mannucci E, Tesi F, Bardini G, et al. Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes. Diabetes Nutr Metab. 2004; 17: 336-342.
16. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32: 193-203.
17. Hu S. Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action. Eur J Pharmacol. 2002; 442: 163-171.
18. Drucker DJ. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab. 2005; 1: 22-31.
19. Tahrani AA, Piya MK, Kennedy A, Barnett AH. Glycaemic control in type 2 diabetes: targets and new therapies. Pharmacol Ther. 2010; 125: 328-361.
20. Palalau AI, Tahrani AA, Piya MK, Barnett AH. DPP-4 inhibitors in clinical practice. Postgrad Med. 2009; 121: 70-100.
21. Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther. 2009; 26: 249-262.
22. Schmitz O, Brock B, Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes. 2004; 53(suppl. 3): S233-S238.
23. Del Prato S, Felton AM, Munro N, Nesto R, Zimmet P, Zinman B. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract. 2005; 59: 1345-1355.
24. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med. 2007; 261: 32-43.
25. Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol. 2001; 280: F10-F18.
26. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis. 2009; 53: 875-883.
27. Chen J, Feder J, Neuhaus I, Whaley JM. Tissue expression profiling of the sodium-glucose cotransporter (SGLT) family: implication for targeting SGLT2 in type 2 diabetes patients. Diabetes. 2008; 57(suppl. 1): A682. Abstract 2493.
28. Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest. 1994; 93: 397-404.
29. Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr. 2003; 89: 3-9.
30. Lee YJ, Lee YJ, Han HJ. Regulatory mechanisms of Na+/glucose cotransporters in renal proximal tubule cells. Kidney Int. 2007; 72: S27-S35.
31. Brooks AM, Thacker SM. Dapagliflozin for the treatment of type 2 diabetes. Ann Pharmacother. 2009; 43: 1286-1293.
32. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodiumdependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2008; 51: 1145-1149.
33. Chao EC, Henry RR. SGLT2 inhibition-a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010; 9: 551-559.
34. Dobbins R, Kapur A, Kapitza C, O'Connor-Semmes R, Tao W, Hussey EK. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2) reduces serum glucose in type 2 diabetes mellitus (T2DM) patients. Diabetes. 2009; 58(suppl. 1). Abstract.
35. Hussey EK, Kapur A, O'Connor-Semmes R, Tao W, Poo J, Dobbins R. Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate (SGLT2 inhibitor) and metformin when coadministered in type 2 diabetes mellitus (T2DM) patients. Diabetes. 2009; 58(suppl. 1). Abstract.
36. Hussey E, Clark RV, Amin DM, et al. Early clinical studies to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of sergliflozin, a novel inhibitor or renal glucose reabsorption, in healthy volunteers and subjects with type 2 diabetes mellitus. Diabetes. 2007; 56: A49. Abstract.
37. Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008; 57: 1723-1729.
38. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009; 85: 520-526.
39. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009; 85: 513-519.
40. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009; 32: 650-657.
41. Wilding JPH, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers. Applicability of a novel insulin-independent treatment. Diabetes Care. 2009; 32: 1656-1662.
42. Wilding JPH, Woo V, Soler NG, Pahor A, Sugg J, Parikh S. Dapagliflozin in patients with type 2 diabetes poorly controlled on insulin therapy-efficacy of a novel insulin-independent treatment. Diabetes. 2010; 59(suppl. 1): A21-A22. Abstract 78-OR.
43. Wilding JPH, Woo V, Soler NG, Pahor A, Sugg J, Parikh S. Sustained effectiveness of dapagliflozin over 48 weeks in patients with type 2 diabetes poorly controlled with insulin. Diabetes. 2010; 59(suppl. 1). Abstract 0021-LB.
44. Soler NG, Wilding JPH, Woo V, et al. Dapagliflozin lowered rate of insulin uptitration/study discontinuation from lack of glycaemic control in 48-week study of type 2 diabetes patients poorly controlled on insulin therapy. Diabetologia. 2010; 53(suppl. 1): S348-S349.
45. Bergenstal RM, Buse J, Glass L, et al. Exenatide added to insulin glargine-treated patients with type 2 diabetes provided excellent fasting and postprandial control with weight loss and no increased risk of hypoglycaemia. Diabetologia. 2010; 53(suppl. 1): S37. Abstract.
46. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care. 2010; 33: 2217-2224.
47. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 375: 2223-2233.
48. Strojek K, Hruba V, Elze M, Langkilde A, Parikh S. Efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus and inadequate glycaemic control on glimepiride monotherapy. Diabetologia. 2010; 53(suppl. 1): S347. Abstract.
49. Nauck M, Del Prato S, Rohwedder K, Elze M, Parikh S. Dapagliflozin vs glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin: 52-week results of a double-blind, randomized, controlled trial. Diabetologia. 2010; 53(suppl 1). Abstract.
50. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010; 5: 133-141.
51. Scholl-Burgi S, Santer R, Ehrich JH. Long-term outcome of renal glucosuria type 0: the original patient and his natural history. Nephrol Dial Transplant. 2004; 19: 2394-2396.